Core Insights - MediWound reported a quarterly loss of $0.24 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.81, representing an earnings surprise of +70.37% [1] - The company posted revenues of $5.43 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 15.52%, but showing an increase from $4.36 million year-over-year [2] - MediWound has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates two times in the same period [2] Financial Performance - The company experienced a loss of $0.98 per share in the same quarter last year, indicating improvement in financial performance [1] - The current consensus EPS estimate for the upcoming quarter is -$0.85 on revenues of $7.7 million, and for the current fiscal year, it is -$2.69 on revenues of $23.79 million [7] Market Position - MediWound shares have increased by approximately 0.3% since the beginning of the year, underperforming compared to the S&P 500's gain of 12.9% [3] - The Zacks Industry Rank for Medical - Drugs is in the top 29% of over 250 Zacks industries, indicating a favorable industry outlook [8] Future Outlook - The sustainability of MediWound's stock price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] - The estimate revisions trend for MediWound was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market [6]

Profound Medical (PROF) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +31.58%. A quarter ago, it was expected that this company would post a loss of $0.43 per share when it actually produced a loss of $0.52, delivering a surprise of -20.93%.Over the last four quarters, the company has sur ...

Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +166.67%. A quarter ago, it was expected that this drugmaker would post a loss of $0.02 per share when it actually produced earnings of $0.14, delivering a surprise of +800%.Over the last four quarters, th ...

Company Performance - Aquestive Therapeutics reported a quarterly loss of $0.14 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.13, representing an earnings surprise of -7.69% [1] - The company posted revenues of $12.81 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 4.13% and down from $13.54 million a year ago [2] - Over the last four quarters, the company has only surpassed consensus EPS estimates once and has not beaten consensus revenue estimates [2] Stock Movement and Outlook - The stock has increased approximately 70.8% since the beginning of the year, significantly outperforming the S&P 500's gain of 15.1% [3] - The future price movement of the stock will largely depend on management's commentary during the earnings call and the earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is -$0.14 on revenues of $14.03 million, and for the current fiscal year, it is -$0.63 on revenues of $46.1 million [7] Industry Context - The Medical - Drugs industry, to which Aquestive Therapeutics belongs, is currently in the top 40% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Core Viewpoint - Xeris Biopharma (XERS) shares experienced a significant increase of 14.2% to $9.27, driven by strong investor expectations regarding its growth prospects and an impressive trading volume [1][2]. Company Performance - The stock's recent price surge is linked to positive investor sentiment about Xeris' marketed drugs, including Recorlev, Gvoke, and Keveyis, which target specific medical conditions [2]. - Xeris is projected to report quarterly earnings of $0.01 per share, reflecting a year-over-year increase of 116.7%, with expected revenues of $74.35 million, up 37% from the previous year [3]. Earnings Estimates - The consensus EPS estimate for Xeris has been revised 60.7% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4]. - The strong earnings estimate revisions suggest potential for continued stock strength in the future [4]. Industry Context - Xeris Biopharma holds a Zacks Rank of 2 (Buy), indicating favorable market conditions compared to its industry peers [5]. - In contrast, Zoetis (ZTS), another company in the same medical-drugs industry, saw a slight decline of 0.9% in its stock price and has a Zacks Rank of 3 (Hold) [5][6].

Core Insights - Zevra Therapeutics (ZVRA) shares increased by 12.3% to close at $11.78, with a notable trading volume, and a total gain of 44.5% over the past four weeks [1][2] Company Performance - The rise in stock price is linked to positive investor sentiment regarding Zevra's growth prospects, particularly due to its drug Miplyffa, which received FDA approval for treating Niemann-Pick disease type C in September 2024, generating $38.6 million in sales during the first half of 2025 [2] - The company is expected to report a quarterly loss of $0.04 per share, reflecting a year-over-year change of +94.2%, with revenues projected at $26.53 million, a significant increase of 619.1% from the previous year [3] - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Zevra Therapeutics is categorized under the Zacks Medical - Drugs industry, which includes other companies like OmniAb, Inc. (OABI), that also experienced a stock increase of 6.2% to $1.71 in the last trading session [5] - OmniAb's consensus EPS estimate for the upcoming report has remained unchanged at -$0.15, representing a year-over-year change of +6.3% [6]

Core Insights - Zoetis (ZTS) has a strong history of beating earnings estimates and is well-positioned for future earnings growth [1][5] - The company has surpassed earnings estimates by an average of 7.18% over the last two quarters [1][5] - The upcoming earnings report is expected on November 4, 2025 [8] Earnings Performance - For the last reported quarter, Zoetis achieved earnings of $1.76 per share, exceeding the Zacks Consensus Estimate of $1.62 per share by 8.64% [2] - In the previous quarter, the company reported earnings of $1.48 per share against an expectation of $1.4 per share, resulting in a surprise of 5.71% [2] Earnings Estimates and Predictions - Estimates for Zoetis have been trending higher, supported by its history of earnings surprises [5] - The company currently has an Earnings ESP of +0.41%, indicating a positive outlook from analysts regarding its earnings prospects [8] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat [8][6]

Company Overview - Aquestive Therapeutics (AQST) shares increased by 14.8% to close at $5.67, with notable trading volume compared to typical sessions, and a total gain of 26.3% over the past four weeks [1][2] Regulatory Developments - The stock price surge is attributed to positive investor expectations regarding the FDA approval filing for its key product candidate, Anaphylm, aimed at treating severe allergic reactions. The FDA waived the advisory committee meeting, indicating a lower perceived risk associated with the treatment, with a final decision expected by January 31, 2026 [2] Financial Performance Expectations - The company is projected to report a quarterly loss of $0.13 per share, unchanged from the previous year, with expected revenues of $13.36 million, reflecting a 1.3% decline from the year-ago quarter [3] - The consensus EPS estimate for the quarter has been revised 24.4% higher over the last 30 days, suggesting a potential for price appreciation [4] Industry Comparison - Aquestive Therapeutics operates within the Zacks Medical - Drugs industry. In contrast, USANA Health Sciences (USNA) closed 3.6% lower at $29.74, with a 0.7% return over the past month. USANA's consensus EPS estimate remains unchanged at $0.47, representing a 16.1% decline from the previous year [4][5]

Core Insights - Zevra Therapeutics reported a quarterly earnings of $1.21 per share, which was below the Zacks Consensus Estimate of $2.19, resulting in an earnings surprise of -44.75% [1] - The company posted revenues of $25.88 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 14.35%, and showing significant growth from $4.45 million in the same quarter last year [2] - The stock has increased approximately 40.3% year-to-date, outperforming the S&P 500's gain of 8.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $24.48 million, while for the current fiscal year, the estimate is $1.36 on revenues of $94.1 million [7] - The estimate revisions trend for Zevra Therapeutics was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which Zevra Therapeutics belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

分组1 - Theravance Biopharma reported a quarterly loss of $0.08 per share, better than the Zacks Consensus Estimate of a loss of $0.14, representing an earnings surprise of +42.86% [1] - The company posted revenues of $26.2 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 53.76%, compared to $14.26 million in the same quarter last year [2] - Theravance Bio shares have increased by approximately 21.2% since the beginning of the year, outperforming the S&P 500's gain of 8.4% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $18.12 million, and for the current fiscal year, it is $0.01 on revenues of $96.03 million [7] - The Medical - Drugs industry, to which Theravance Bio belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook [8]